PMID- 22735048
OWN - NLM
STAT- MEDLINE
DCOM- 20121025
LR  - 20211021
IS  - 1547-5646 (Electronic)
IS  - 1547-5654 (Print)
IS  - 1547-5646 (Linking)
VI  - 17
IP  - 2
DP  - 2012 Aug
TI  - Dietary therapy to promote neuroprotection in chronic spinal cord injury.
PG  - 134-40
LID - 10.3171/2012.5.SPINE1216 [doi]
AB  - OBJECT: The pathogenesis of cervical spondylotic myelopathy (CSM) is related to 
      both primary mechanical and secondary biological injury. The authors of this 
      study explored a novel, noninvasive method of promoting neuroprotection in 
      myelopathy by using curcumin to minimize oxidative cellular injury and the 
      capacity of omega-3 fatty acids to support membrane structure and improve 
      neurotransmission. METHODS: An animal model of CSM was created using a 
      nonresorbable expandable polymer placed in the thoracic epidural space, which 
      induced delayed myelopathy. Animals that underwent placement of the expandable 
      polymer were exposed to either a diet rich in docosahexaenoic acid and curcumin 
      (DHA-Cur) or a standard Western diet (WD). Twenty-seven animals underwent serial 
      gait testing, and spinal cord molecular assessments were performed after the 
      6-week study period. RESULTS: At the conclusion of the study period, gait 
      analysis revealed significantly worse function in the WD group than in the 
      DHA-Cur group. Levels of brain-derived neurotrophic factor (BDNF), syntaxin-3, 
      and 4-hydroxynonenal (4-HNE) were measured in the thoracic region affected by 
      compression and lumbar enlargement. Results showed that BDNF levels in the 
      DHA-Cur group were not significantly different from those in the intact animals 
      but were significantly greater than in the WD group. Significantly higher lumbar 
      enlargement syntaxin-3 in the DHA-Cur animals combined with a reduction in lipid 
      peroxidation (4-HNE) indicated a possible healing effect on the plasma membrane. 
      CONCLUSIONS: Data in this study demonstrated that DHA-Cur can promote spinal cord 
      neuroprotection and neutralize the clinical and biochemical effects of 
      myelopathy.
FAU - Holly, Langston T
AU  - Holly LT
AD  - Department of Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles, 
      CA 90095-6901, USA. lholly@mednet.ucla.edu
FAU - Blaskiewicz, Donald
AU  - Blaskiewicz D
FAU - Wu, Aiguo
AU  - Wu A
FAU - Feng, Cameron
AU  - Feng C
FAU - Ying, Zhe
AU  - Ying Z
FAU - Gomez-Pinilla, Fernando
AU  - Gomez-Pinilla F
LA  - eng
GR  - R01 NS050465/NS/NINDS NIH HHS/United States
GR  - R01 NS056413/NS/NINDS NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20120626
PL  - United States
TA  - J Neurosurg Spine
JT  - Journal of neurosurgery. Spine
JID - 101223545
RN  - 0 (Aldehydes)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Qa-SNARE Proteins)
RN  - 25167-62-8 (Docosahexaenoic Acids)
RN  - K1CVM13F96 (4-hydroxy-2-nonenal)
SB  - IM
MH  - Aldehydes/blood
MH  - Animals
MH  - Brain-Derived Neurotrophic Factor/blood
MH  - Chronic Disease
MH  - Curcuma/drug effects/*metabolism
MH  - Diet/methods
MH  - *Disease Models, Animal
MH  - Docosahexaenoic Acids/*administration & dosage/pharmacology
MH  - Male
MH  - Neuroprotective Agents/*administration & dosage/pharmacology
MH  - Qa-SNARE Proteins/blood
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Spinal Cord Injuries/*drug therapy/etiology/*metabolism
PMC - PMC3951955
MID - NIHMS468264
EDAT- 2012/06/28 06:00
MHDA- 2012/10/26 06:00
PMCR- 2014/03/13
CRDT- 2012/06/28 06:00
PHST- 2012/06/28 06:00 [entrez]
PHST- 2012/06/28 06:00 [pubmed]
PHST- 2012/10/26 06:00 [medline]
PHST- 2014/03/13 00:00 [pmc-release]
AID - 10.3171/2012.5.SPINE1216 [doi]
PST - ppublish
SO  - J Neurosurg Spine. 2012 Aug;17(2):134-40. doi: 10.3171/2012.5.SPINE1216. Epub 
      2012 Jun 26.